Go Pro
→ Major Buy Alert Issued for September 30th (From TradeSmith) (Ad)tc pixel Free ENTO Stock Alerts

Entero Therapeutics (ENTO) Competitors

Entero Therapeutics logo
$2.97 -0.49 (-14.16%)
As of 09/3/2026
Compare

ENTO vs. STIX, YMT, MNDO, BTCT, and ANY

Should you buy Entero Therapeutics stock or one of its competitors? Entero Therapeutics's main competitors and comparable companies include Semantix (STIX), Yimutian (YMT), MIND C.T.I. (MNDO), BTC Digital (BTCT), and Sphere 3D (ANY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Entero Therapeutics compare to Semantix?

Entero Therapeutics (NASDAQ:ENTO) and Semantix (NASDAQ:STIX) are both small-cap technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Entero Therapeutics has a net margin of 0.00% compared to Semantix's net margin of -69.49%. Semantix's return on equity of -45.45% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Entero TherapeuticsN/A -461.02% -14.72%
Semantix -69.49%-45.45%-26.98%

Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Semantix has a beta of -0.37, indicating that its stock price is 137% less volatile than the broader market.

Given Semantix's higher possible upside, analysts clearly believe Semantix is more favorable than Entero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Semantix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Entero Therapeutics has higher earnings, but lower revenue than Semantix. Entero Therapeutics is trading at a lower price-to-earnings ratio than Semantix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A
Semantix$264.23M0.00-$63.61M-$0.81N/A

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled Semantix'saverage media sentiment score.

Company Overall Sentiment
Entero Therapeutics Neutral
Semantix Neutral

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 40.1% of Semantix shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Comparatively, 35.5% of Semantix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Semantix beats Entero Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Entero Therapeutics compare to Yimutian?

Yimutian (NASDAQ:YMT) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap technology companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

Yimutian's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
YimutianN/A N/A N/A
Entero Therapeutics N/A -461.02%-14.72%

12.3% of Entero Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Yimutian has higher revenue and earnings than Entero Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yimutian$20.11M0.05-$6.67MN/AN/A
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A

In the previous week, Yimutian's average media sentiment score of 0.00 equaled Entero Therapeutics'average media sentiment score.

Company Overall Sentiment
Yimutian Neutral
Entero Therapeutics Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Yimutian
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Yimutian beats Entero Therapeutics on 4 of the 6 factors compared between the two stocks.

How does Entero Therapeutics compare to MIND C.T.I.?

Entero Therapeutics (NASDAQ:ENTO) and MIND C.T.I. (NASDAQ:MNDO) are both small-cap technology companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 24.3% of MIND C.T.I. shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled MIND C.T.I.'saverage media sentiment score.

Company Overall Sentiment
Entero Therapeutics Neutral
MIND C.T.I. Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
MIND C.T.I.
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Entero Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, MIND C.T.I. has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

MIND C.T.I. has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than MIND C.T.I., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A
MIND C.T.I.$19.46M1.05$2.60M$0.166.31

MIND C.T.I. has a net margin of 16.87% compared to Entero Therapeutics' net margin of 0.00%. MIND C.T.I.'s return on equity of 14.09% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Entero TherapeuticsN/A -461.02% -14.72%
MIND C.T.I. 16.87%14.09%10.90%

Summary

MIND C.T.I. beats Entero Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Entero Therapeutics compare to BTC Digital?

Entero Therapeutics (NASDAQ:ENTO) and BTC Digital (NASDAQ:BTCT) are both small-cap technology companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

In the previous week, BTC Digital had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 1 mentions for BTC Digital and 0 mentions for Entero Therapeutics. BTC Digital's average media sentiment score of 1.05 beat Entero Therapeutics' score of 0.00 indicating that BTC Digital is being referred to more favorably in the news media.

Company Overall Sentiment
Entero Therapeutics Neutral
BTC Digital Positive

BTC Digital has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than BTC Digital, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A
BTC Digital$14.04M1.19-$9.06M-$1.20N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BTC Digital
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 7.3% of BTC Digital shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Comparatively, 0.2% of BTC Digital shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BTC Digital's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Entero TherapeuticsN/A -461.02% -14.72%
BTC Digital N/A N/A N/A

Entero Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, BTC Digital has a beta of 5.85, indicating that its share price is 485% more volatile than the broader market.

Summary

BTC Digital beats Entero Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Entero Therapeutics compare to Sphere 3D?

Entero Therapeutics (NASDAQ:ENTO) and Sphere 3D (NASDAQ:ANY) are both small-cap technology companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled Sphere 3D'saverage media sentiment score.

Company Overall Sentiment
Entero Therapeutics Neutral
Sphere 3D Neutral

Entero Therapeutics has higher earnings, but lower revenue than Sphere 3D. Entero Therapeutics is trading at a lower price-to-earnings ratio than Sphere 3D, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A
Sphere 3D$11.18M1.81-$21.48M-$3.68N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Sphere 3D
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 17.3% of Sphere 3D shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Comparatively, 6.4% of Sphere 3D shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Entero Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Sphere 3D has a beta of 3.32, indicating that its share price is 232% more volatile than the broader market.

Entero Therapeutics has a net margin of 0.00% compared to Sphere 3D's net margin of -332.50%. Sphere 3D's return on equity of -111.12% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Entero TherapeuticsN/A -461.02% -14.72%
Sphere 3D -332.50%-111.12%-94.02%

Summary

Sphere 3D beats Entero Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENTO vs. The Competition

Export
MetricEntero TherapeuticsSoftware IndustryTechnology SectorNASDAQ Exchange
Market Cap$4.72M$15.82B$29.87B$12.89B
Dividend YieldN/A3.40%2.73%8.57%
P/E Ratio-1.76139.7376.1725.40
Price / SalesN/A1,292.60593.5198.88
Price / CashN/A45.8947.3252.27
Price / Book-1.217.399.256.17
Net Income-$18.06M$437.25M$679.28M$349.50M
7 Day Performance-25.94%-1.66%-0.88%-0.05%
1 Month Performance2.06%0.84%-1.10%0.80%
1 Year Performance12.08%5.09%187.79%15.58%

Entero Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENTO
Entero Therapeutics
N/A$2.97
-14.2%		N/A+24.9%$4.72MN/AN/A9
STIX
Semantix
N/AN/AN/AN/A$23.73M$264.23MN/A4
YMT
Yimutian
N/A$2.92
+5.0%		N/A-99.7%$22.28M$20.11MN/A573
MNDO
MIND C.T.I.
0.8542 of 5 stars		$1.03
+1.8%		N/A-18.4%$20.75M$19.46M6.43160
BTCT
BTC Digital
0.2849 of 5 stars		$2.15
+2.3%		N/A-22.9%$20.45M$14.04MN/A16

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ENTO) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Anthropic’s $65 Billion Surge: One backdoor got there first
Anthropic's annualized revenue run rate hit $65 billion, up from $47 billion in May and roughly $9 billion at ...
The Oxford Club | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Congress Just Opened the Floodgates
The House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...
Awesomely | Sponsoredtc pixel
Near retirement? Buy this stock
On August 9, the Wall Street Journal profiled a unique AI strategy used by three companies. Whitney Tilson of ...
Stansberry Research | Sponsoredtc pixel
Trump’s “new Petrodollar” exposed
Trump has reportedly secured control over 65 billion barrels across 17 Venezuelan oil fields, more than the en...
Porter & Company | Sponsoredtc pixel